What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results
Myriad Genetics (NASDAQ: MYGN) stock soared earlier this month after the announcement that UnitedHealth Group will begin covering its GeneSight Psychotropic test beginning in October 2019. But investors hoping for more momentum with Myriad's latest quarterly results were sorely disappointed.
The molecular diagnostics company announced its fourth-quarter results after the market closed on Tuesday. Its stock sank 14% in after-hours trading. Here's what you'll want to know about Myriad's Q4 update.
Image source: Getty Images.
Source Fool.com
